nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

15.09.2020 | Original Article

Change in species distribution and antifungal susceptibility of candidemias in an intensive care unit of a university hospital (10-year experience)

verfasst von: Bilgul Mete, Esra Yerlikaya Zerdali, Gokhan Aygun, Nese Saltoglu, Ilker Inanc Balkan, Ridvan Karaali, Sibel Yildiz Kaya, Berna Karaismailoglu, Abdurrahman Kaya, Seval Urkmez, Gunay Can, Fehmi Tabak, Recep Ozturk

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Candidemia is a nosocomial infection mostly found in critically ill patients. Our objectives were to evaluate the change in distribution and resistance profile of Candida spp. isolated from candidemic patients in our intensive care unit over two 5-year periods spanning 15 years and to evaluate the risk factors. Records from the microbiology laboratory were obtained, from January 2004 to December 2008 and from January 2013 to December 2017, retrospectively. Antifungal susceptibility was performed by E-test and evaluated according to EUCAST breakpoints. A total of 210 candidemia cases occurred; 238 Candida spp. were isolated in 197 patients (58.8% male; mean age, 59.2 ± 19.6 years). The most predominant risk factor was central venous catheter use. Species distribution rates were 32%, 28%, 17%, and 11% for C. albicans (n = 76), C. parapsilosis (n = 67), C. glabrata (n = 40), and C. tropicalis (n = 27), respectively. Resistance rate to anidulafungin was high in C. parapsilosis over both periods and increased to 73% in the second period. Fluconazole showed a remarkable decrease for susceptibility in C. parapsilosis (94 to 49%). The prevalence of MDR C. parapsilosis (6%/33%) and C. glabrata (0%/44%) increased in the second period. We observed a predominance of non-albicans Candida spp., with C. parapsilosis being the most frequent and C. glabrata infections presenting with the highest mortality. High level of echinocandin resistance in C. parapsilosis and increasing prevalences of MDR C. parapsilosis and C. glabrata seem emerging challenges in our institution.

Bassetti M, Peghin M, Timsit JF (2016) The current treatment landscape: candidiasis. J Antimicrob Chemother 71(suppl 2):ii13–ii22PubMedCrossRef

Kullberg BJ, Arendrup MC (2015) Invasive candidiasis. N Engl J Med 373(15):1445–1456PubMedCrossRef

Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR et al (2012) Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis 55:1352–1361PubMedCrossRef

Klingspor L, Tortorano AM, Peman J, Willinger B, Hamal P, Sendid B et al (2015) Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM)(2006–2008). Clin Microbiol Infect 21:87PubMedCrossRef

Tan BH, Chakrabarti A, Li RY, Patel AK, Watcharananan SP, Liu Z, Asia Fungal Working Group (AFWG) et al (2015) Incidence and species distribution of candidaemia in Asia: a laboratory-based surveillance study. Clin Microbiol Infect 21(10):946–953PubMedCrossRef

Eggiman P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3:685–702CrossRef

Sellami A, Sellami H, Neji S, Makni F, Abbes S, Cheikhrouhou F et al (2011) Antifungal susceptibility of bloodstream Candida isolates in Sfax Hospital: Tunisia. Mycopathologia 171(6):417–422PubMedCrossRef

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L et al (2016) Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62(4):e1–e50PubMedCrossRef

Schelenz S (2008) Management of candidiasis in the intensive care unit. J Antimicrob Chemother 61(Suppl 1):i31–i34PubMedCrossRef

10.

Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ et al (2009) Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 48:1695–1703PubMedCrossRef

11.

Wan Ismail WNA, Jasmi N, Khan TM, Hong YH, Neoh CF (2019) The economic burden of candidemia and invasive candidiasis: a systematic review. Value Health Reg Issues 21:53–58PubMedCrossRef

12.

Pfaller MA, Diekema DJ (2010) Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36:1–53PubMedCrossRef

13.

Nucci M, Queiroz-Telles F, Tobon AM, Restrepo A, Colombo AL (2010) Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 51:561–570PubMedCrossRef

14.

Wang H, Xiao M, Chen SC, Kong F, Sun ZY, Liao K et al (2012) In vitro susceptibilities of yeast species to fluconazole and voriconazole as determinedby the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. J Clin Microbiol 50:3952–3959PubMedPubMedCentralCrossRef

15.

Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN (2019) Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997-2016. Open Forum Infect Dis 6(Suppl 1):S79–S94PubMedPubMedCentralCrossRef

16.

Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I (2007) The changing epidemiology of invasive candidiasis. Cancer 112:2334–2337

17.

Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR et al (1996) The changing face of candidemia : emergence of non C. albicans species and antifungal resistance. Am J Med 100:617–623PubMedCrossRef

18.

Kontoyiannis DP, Lewis RE (2002) Antifungal drug resistance of pathogenic fungi. Lancet 359:1135–1144PubMedCrossRef

19.

Chapman B, Slavin M, Marriott D, Halliday C, Kidd S, Arthur I, et al, Australian and New Zealand Mycoses Interest Group (2017= changing epidemiology of candidaemia in Australia. J Antimicrob Chemother. 2017;72:1103–8.

20.

Trouve C, Blot S, Hayette MP, Jonckheere S, Patteet S, Rodriguez-Villalobos H et al (2017) Epidemiology and reporting of candidaemia in Belgium: a multi-Centre study. Eur J Clin Microbiol Infect Dis 36:649–655PubMedCrossRef

21.

Pinhati HM, Casulari LA, Souza AC, Siqueira RA, Damasceno CM, Colombo AL (2016) Outbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit. BMC Infect Dis 16:433PubMedPubMedCentralCrossRef

22.

Alp S, Arikan-Akdagli S, Gulmez D, Ascioglu S, Uzun O, Akova M (2015) Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010. Mycoses 58(8):498–505PubMedCrossRef

23.

Yeşilkaya A, Azap Ö, Aydın M, Akçil Ok M (2017) Epidemiology, species distribution, clinical characteristics and mortality of candidemia in a tertiary care university hospital in Turkey, 2007-2014. Mycoses 60(7):433–449PubMedCrossRef

24.

Kazak E, Akın H, Ener B, Sığırlı D, Özkan Ö, Gürcüoğlu E et al (2014) An investigation of Candida species isolated from blood cultures during 17 years in a university hospital. Mycoses 57(10):623–629PubMedCrossRef

25.

Arikan-Akdagli S, Gülmez D, Doğan Ö, Çerikçioğlu N, Doluca Dereli M, Birinci A et al (2019) First multicentre report of in vitro resistance rates in candidaemia isolates in Turkey. J Glob Antimicrobiol Res 18:230–234CrossRef

26.

Arendrup MC, Patterson TF (2017) Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis 216(3):S445–S451PubMedCrossRef

27.

Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, the Global Surveillance Group et al (2010) Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 48:1366–1377PubMedPubMedCentralCrossRef

28.

Vaezi A, Fakhim H, Khodavaisy S, Alizadeh A, Nazeri M, Soleimani A et al (2017) Epidemiological and mycological characteristics of candidemia in Iran: a systematic review and meta-analysis. J Mycol Med 27(2):146–152PubMedCrossRef

29.

Zhou ZL, Lin CC, Chu WL, Yang YL, Lo HJ, TSARY Hospitals (2016) The distribution and drug susceptibilities of clinical Candida species in TSARY 2014. Diagn Microbiol Infect Dis 86(4):399–404PubMedCrossRef

30.

Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M et al (2015) Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 41:285–295PubMedCrossRef

31.

Govender NP, Patel J, Magobo RE, Naicker S, Wadula J, Whitelaw A, TRAC-South Africa group et al (2016) Emergence of azole-resistant Candida parapsilosis causing bloodstream infection: results from laboratory-based sentinel surveillance in South Africa. J Antimicrob Chemother 71:1994–2004PubMedCrossRef

32.

Montagna MT, Lovero G, Borghi E, Amato G, Andreoni S, Campion L et al (2014) Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. Eur Rev Med Pharmacol Sci 18(5):661–674PubMed

33.

Tukenmez Tigen E, Bilgin H, Perk Gurun H, Dogru A, Ozben B, Cerikcioglu N et al (2017) Risk factors, characteristics, and outcomes of candidemia in an adult intensive care unit in Turkey. Am J Infect Control 45(6):e61–e63PubMedCrossRef

34.

Horasan ES, Ersöz G, Göksu M, Otag F, Kurt AO, Karaçorlu S et al (2010) Increase in Candida parapsilosis fungemia in critical care units: a 6-years study. Mycopathologia. 170(4):263–268PubMedCrossRef

35.

Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163PubMedPubMedCentralCrossRef

36.

Lockhart SR, Messer SA, Pfaller MA, Diekema DJ (2008) Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 46:2659–2664PubMedPubMedCentralCrossRef

37.

Forrest GN, Weekes E, Johnson JK (2008) Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Inf Secur 56:126–129

38.

Playford EG, Marriott D, Nguyen Q, Chen S, Ellis D, Slavin M et al (2008) Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 36:2034PubMedCrossRef

39.

Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D et al (2008) Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 46:1206PubMedCrossRef

40.

Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II et al (2009) Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007). Cancer 115:4745–4752PubMedCrossRef

41.

Kollef M, Micek S, Hampton N, Doherty JA, Kumar A (2012) Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 54 /12:1739CrossRef

42.

Andes DR, Safdar N, Baddley JW, Playford G, Rebolş AC, Rex JH, Mycoses Study Group et al (2012) Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54(8):1110PubMedCrossRef

43.

Spellberg BJ, Filler SG, Edwards JE Jr (2006) Current treatment strategies for disseminated candidiasis. Clin Infect Dis 42:244PubMedCrossRef

44.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S et al (2008) In vitro susceptibilities of invasive isolates of Candida spp. to anidulafungin, caspofungin and micafungin: six years of global surveillance. J Clin Microbiol 46:150–156PubMedCrossRef

45.

Hesstvedt L, Gaustad P, Andersen CT, Haarr E, Hannula R, Haukland HH et al (2015) Twenty-two years of candidaemia surveillance: results from a Norwegian national study. Clin Microbiol Infect 21(10):938–945PubMedCrossRef

46.

Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. CLSI document M27-S4. 2012; Clinical and Laboratory Standards Institute

47.

Israel S, Amit S, Israel A, Livneh A, Nir-Paz R, Korem M (2019) The epidemiology and susceptibility of candidemia in Jerusalem, Israel. Front Cell Infect Microbiol 9:352PubMedPubMedCentralCrossRef

48.

Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC (2005) Candida orthoplosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 43:284–292PubMedPubMedCentralCrossRef

49.

Gonçalves SS, Amorim CS, Nucci M, Padovan AC, Briones MR, Melo AS et al (2010) Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidemia in Brazil. Clin Microbiol Infect 16(7):885–887PubMedCrossRef

50.

Gomez-Lopez A, Alastruey-Izquierdo A, Rodriguez D, Almirante B, Pahissa A, Rodriguez-Tudela JL, Barcelona Candidemia Project Study Group et al (2008) Barcelona Candidemia project study group prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 52:1506–1509PubMedPubMedCentralCrossRef

51.

Perlin DS (2015) Echinocandin resistance in Candida. Clin Infect Dis 61(6):S612–S617PubMedPubMedCentralCrossRef

52.

Szabó Z, Szilágyi J, Tavanti A, Kardos G, Rozgonyi F, Bayegan S et al (2009) In vitro efficacy of 5 antifungal agents against C. parapsilosis, Candida orthopsilosis and Candida metapsilosis as determined by time-kill methodology. Diagn Microbiol Infect 64:283–288CrossRef

53.

Borghi E, Sciota R, Iatta R, Biassoni C, Montagna MT, Morace G (2011) Characterization of Candida parapsilosis complex strains isolated from invasive fungal infections. Eur J Clin Microbiol Infect Dis 30(11):1437–1441PubMedCrossRef

54.

Alexander BD, Byrne TC, Smith KL, Hanson KE, Anstrom KJ, Perfect JR et al (2007) Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol 45(3):698–706PubMedPubMedCentralCrossRef

55.

Arikan S (2007) Current status of antifungal susceptibility testing methods. Med Mycol 45:569–587PubMedCrossRef

56.

Metin DY, Hilmioglu Polat S, Samlioglu P, Doganay Oflazoglu B, Inci RI, Tumbay E (2011) Evaluation of antifungal susceptibility testing with microdilution and E test methods of Candida blood isolates. Mycopathologia 172(3):187–199PubMedCrossRef

57.

Morace G, Borghi E, Iatta R, Amato G, Anderoni S, Brigante G et al (2011) Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients. BMC Infect Dis 11:130–138PubMedPubMedCentralCrossRef

58.

Lovero G, Borghi E, Balbino S, Cirasola D, De Giglio O, Perdoni F et al (2016) Molecular identification and echinocandin susceptibility of candida parapsilosis complex bloodstream isolates in Italy, 2007-2014. PLoS One 11(2):e0150218PubMedPubMedCentralCrossRef

Titel: Change in species distribution and antifungal susceptibility of candidemias in an intensive care unit of a university hospital (10-year experience)
verfasst von: Bilgul Mete
Esra Yerlikaya Zerdali
Gokhan Aygun
Nese Saltoglu
Ilker Inanc Balkan
Ridvan Karaali
Sibel Yildiz Kaya
Berna Karaismailoglu
Abdurrahman Kaya
Seval Urkmez
Gunay Can
Fehmi Tabak
Recep Ozturk
Publikationsdatum: 15.09.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 2/2021
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-020-03994-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Change in species distribution and antifungal susceptibility of candidemias in an intensive care unit of a university hospital (10-year experience)

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Outbreak of multi-drug-resistant (MDR) Shigella flexneri in northern Australia due to an endemic regional clone acquiring an IncFII plasmid

Prevalence and outcomes of re-positive nucleic acid tests in discharged COVID-19 patients

Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach

Evaluation of three commercial assays for SARS-CoV-2 molecular detection in upper respiratory tract samples

Rapid detection of carbapenemase-producing organisms directly from blood cultures positive for Gram-negative bacilli

Molecular epidemiology and antifungal susceptibilities of Cryptococcus species isolates from HIV and non-HIV patients in Southwest China

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin